Canaccord Genuity Reiterates a 'Buy' on Teva Pharma (TEVA); Thesis Continues Playing Out - Copaxone Decision Key to Next Leg Up
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Price: $37.34 +1.44%
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Teva Pharma (NASDAQ: TEVA) price target of $52.00.
Analyst, Randall Stanicky, said, "TEVA posted a clean and solid Q4 in contrast to what we’ve seen in recent quarters. That said, what helped drive the stock was the 25% boost to the dividend which is a further endorsement of the shifting focus at the company. Going forward, our thesis has been pegged to (1) a better 2012 on a “headwinds to tailwinds” outlook; (2) structural change in the free cash pay-out via buy-back and dividend and (3) sustainable EPS growth ahead. We now have solid visibility on the first two. On the third, we continue to see growth ahead on a diversified base though recognize that visibility around the Copaxone litigation will likely be needed for the next leg up."
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $45.04 yesterday.
Analyst, Randall Stanicky, said, "TEVA posted a clean and solid Q4 in contrast to what we’ve seen in recent quarters. That said, what helped drive the stock was the 25% boost to the dividend which is a further endorsement of the shifting focus at the company. Going forward, our thesis has been pegged to (1) a better 2012 on a “headwinds to tailwinds” outlook; (2) structural change in the free cash pay-out via buy-back and dividend and (3) sustainable EPS growth ahead. We now have solid visibility on the first two. On the third, we continue to see growth ahead on a diversified base though recognize that visibility around the Copaxone litigation will likely be needed for the next leg up."
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $45.04 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
